These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

745 related items for PubMed ID: 12351435

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
    Kruszynska YT, Yu JG, Olefsky JM, Sobel BE.
    Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
    [Abstract] [Full Text] [Related]

  • 3. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
    Frias JP, Yu JG, Kruszynska YT, Olefsky JM.
    Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970
    [Abstract] [Full Text] [Related]

  • 4. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.
    Miyazaki Y, He H, Mandarino LJ, DeFronzo RA.
    Diabetes; 2003 Aug; 52(8):1943-50. PubMed ID: 12882909
    [Abstract] [Full Text] [Related]

  • 5. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.
    DeFronzo RA, Barzilai N, Simonson DC.
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1294-301. PubMed ID: 1955512
    [Abstract] [Full Text] [Related]

  • 6. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
    Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA.
    J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy.
    Phillips SA, Ciaraldi TP, Kong AP, Bandukwala R, Aroda V, Carter L, Baxi S, Mudaliar SR, Henry RR.
    Diabetes; 2003 Mar; 52(3):667-74. PubMed ID: 12606507
    [Abstract] [Full Text] [Related]

  • 9. Adiponectin and its response to thiazolidinediones are associated with insulin-mediated glucose metabolism in type 2 diabetic patients and their first-degree relatives.
    Hulstrøm V, Højlund K, Vinten J, Beck-Nielsen H, Levin K.
    Diabetes Obes Metab; 2008 Nov; 10(11):1019-28. PubMed ID: 18284435
    [Abstract] [Full Text] [Related]

  • 10. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats.
    Kramer D, Shapiro R, Adler A, Bush E, Rondinone CM.
    Metabolism; 2001 Nov; 50(11):1294-300. PubMed ID: 11699047
    [Abstract] [Full Text] [Related]

  • 11. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes.
    Tonelli J, Li W, Kishore P, Pajvani UB, Kwon E, Weaver C, Scherer PE, Hawkins M.
    Diabetes; 2004 Jun; 53(6):1621-9. PubMed ID: 15161771
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
    Yu JG, Kruszynska YT, Mulford MI, Olefsky JM.
    Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
    [Abstract] [Full Text] [Related]

  • 14. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients.
    Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, Chuang LM.
    Diabetes Care; 2002 Feb; 25(2):376-80. PubMed ID: 11815513
    [Abstract] [Full Text] [Related]

  • 15. Evidence for a potent antiinflammatory effect of rosiglitazone.
    Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P.
    J Clin Endocrinol Metab; 2004 Jun; 89(6):2728-35. PubMed ID: 15181049
    [Abstract] [Full Text] [Related]

  • 16. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
    Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI.
    Ann Intern Med; 1998 Feb 01; 128(3):176-85. PubMed ID: 9454525
    [Abstract] [Full Text] [Related]

  • 17. Plasma adiponectin and insulin resistance in Korean type 2 diabetes mellitus.
    Kim MJ, Yoo KH, Park HS, Chung SM, Jin CJ, Lee Y, Shin YG, Chung CH.
    Yonsei Med J; 2005 Feb 28; 46(1):42-50. PubMed ID: 15744804
    [Abstract] [Full Text] [Related]

  • 18. [The effect of rosiglitazone on plasma adiponectin and resistin levels in obese PCO woman--preliminary report].
    Jakubowska J, Bohdanowicz-Pawlak A, Milewicz A.
    Przegl Lek; 2007 Feb 28; 64(2):70-3. PubMed ID: 17892035
    [Abstract] [Full Text] [Related]

  • 19. [Insulin-sensitizing agents: metformin and thiazolidinedione derivatives].
    Satoh J.
    Nihon Rinsho; 2003 Jul 28; 61(7):1224-9. PubMed ID: 12877089
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.